GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abcam PLC (OTCPK:ABCZF) » Definitions » Construction In Progress

Abcam (ABCZF) Construction In Progress : $0.0 Mil (As of Jun. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Abcam Construction In Progress?


Abcam Construction In Progress Historical Data

The historical data trend for Abcam's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abcam Construction In Progress Chart

Abcam Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec22
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Abcam Semi-Annual Data
Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Jun22 Dec22 Jun23
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Abcam Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


Abcam (ABCZF) Business Description

Traded in Other Exchanges
N/A
Address
Discovery Drive, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AX
Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.